Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Brief Report
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Use advanced search instead (articles only)
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Oncology
Vol. 4, Issue 2, 2017
October 26, 2016 EDT
A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Margaret Hux
,
Denise Zou
,
Esprit Ma
,
Peter Sajosi
,
Andreas Engstrom
,
Ross Selby
,
Eugene Benson
,
Andrew Briggs
,
Vijayveer Bonthapally
,
incremental cost-effectiveness ratio
quality-adjusted life year
chemotherapy
systemic anaplastic large cell lymphoma
brentuximab vedotin
cost-effectiveness
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9820
JHEOR
1.
Hux M, Zou D, Ma E, et al. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
JHEOR
. 2016;4(2):188-203.
doi:10.36469/9820
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats